Hitting the pause button on development in embryos has implications for understanding aging.

UC San Francisco researchers have found a way to pause the development of early mouse embryos for up to a month in the lab, a finding with potential implications for assisted reproduction, regenerative medicine, aging, and even cancer, the authors say.

The new study—published online November 23, 2016 in Nature —involved experiments with pre-implantation mouse embryos, called blastocysts. The researchers found that drugs that inhibit the activity a master regulator of cell growth called mTOR can put these early embryos into a stable and reversible state of suspended animation.

“Normally, blastocysts only last a day or two, max, in the lab. But blastocysts treated with mTOR inhibitors could survive up to 4 weeks,” said the study’s lead author, Aydan Bulut-Karslioglu, PhD, a post-doctoral researcher in the lab of senior author Miguel Ramalho-Santos, PhD, who is an associate professor of obstetrics/gynecology and reproductive sciences at UCSF.

Progress towards making a blood scrubber to calibrate the pro aging factors in blood. Irina Conboy has spent the last 20 years working on parabiosis and signalling factors in blood and this is yet another step forward for their research.

Whilst many are seeking the secret sauce in young blood the data suggests it is much more likely the case that old blood contains too many pro-aging factors eg, TGF-beta, TNF-a, IL-6, CD38 etc… The aim is now to filter old blood and calibrate such factors in order to promote a pro-youthful signalling environment. If only this device was small enough to wear or implant.

In what could be a fresh chapter in the never-ending story of the search for eternal youth, scientists are to tinker with people’s blood in the hope of slowing down the ageing process and preventing age-related diseases.

Researchers in California plan to launch a clinical trial of the radical – and highly experimental – approach in the next six months, after a small study in mice found the treatment had promise.

Destroying and replacing the immune system is one of the approaches to treat the aging process.

Fightaging! provides some commentary about the immune system in relation to aging. Addressing the decline of the immune system is one of the approaches SRF is interested in and is a cornerstone of rejuvenation biotechnology.

“Understanding exactly how aging progressively harms the intricate choreography of the immune response is a massive project, and nowhere near completion. It is possible to judge how far along researchers are in this work by the side effect of the quality of therapies for autoimmune disease, which are malfunctions in immune configuration, and largely incurable at the present time. From a practical point of view, and as mentioned above, the best prospects for effective treatments in the near future involve destroying and recreating the immune system. That works around our comparative ignorance by removing all of the problems that researchers don’t understand in addition to ones that they do.”

#sens #aging

This gives a very simple summary of the process of drug development.

The development process from Pre-Clinical testing to an approved product we can use is a long one. A global average of 17 years with the US being 12 years is the historical norm for new drugs and therapies to be developed.

#aging #crowdfundthecure

Happy Thanksgiving! This year during your holiday meal, share what you are thankful for and think about how to pay it forward on #GivingTuesday.

We are working hard to treat age-related diseases so that we all get to enjoy more wonderful days together like this. We need your help to do it.

#sens

Speculation about what order rejuvenation biotechnologies will arrive.

The first rejuvenation therapies to work well enough to merit the name will be based on the SENS vision: that aging is at root caused by a few classes of accumulated cell and tissue damage, and biotechnologies that either repair that damage or render it irrelevant will as a result produce rejuvenation. Until very recently, no medical technology could achieve this goal, and few research groups were even aiming for that outcome. We are in the midst of a grand transition, however, in which the research and development community is finally turning its attention to the causes of aging, understanding that this is the only way to effectively treat and cure age-related disease. Age-related diseases are age-related precisely because they are caused by the same processes of damage that cause aging: the only distinctions between aging and disease are the names given to various collections of symptoms. All of frailty, disease, weakness, pain, and suffering in aging is the result of accumulated damage at the level of cells and protein machinery inside those cells. Once the medical community becomes firmly set on the goal of repairing that damage, we’ll be well on the way to controlling and managing aging as a chronic condition — preventing it from causing harm to the patient by periodically repairing and removing its causes before they rise to the level of producing symptoms and dysfunction. The therapies of the future will be very different from the therapies of the past.

The full rejuvenation toolkit of the next few decades will consist of a range of different treatments, each targeting a different type of molecular damage in cells and tissues. In this post, I’ll take a look at the likely order of arrival of some of these therapies, based on what is presently going on in research, funding, and for-profit development. This is an update to a similar post written four years ago, now become somewhat dated given recent advances in the field. Circumstances change, and considerable progress has been made in some lines of research and development.

1) Clearance of Senescent Cells